Vaccines Areas Of Interest

Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on A proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Pfizer Global Reviewers. A formal notification regarding the status of your application will be sent once a decision is reached. Pfizer support will only be extended upon the execution of a research agreement. For any questions, please send an email to [email protected] .


Requests will only be accepted in response to Request for Proposals under Pfizer’s Competitive Grant Program.

Research areas to be considered for Pfizer support include:

  1. Understand impact of COVID on communities, spectrum of disease in communities, and level of herd immunity.
  2. Postmortem Analysis of deceased persons with known or suspected COVID-19


Research areas to be considered for Pfizer support include:

  1. Evolving epidemiology
    1. Clinical disease burden in different:
      1. age cohorts (e.g., adolescents, infants)
      2. settings (e.g., universities, military, mass gathering, travelers)
      3. clinical condition or patient population (e.g., individuals at increased risk of meningococcal disease)
    2. Nasopharyngeal carriage in different age cohorts and settings (examples above)
    3. Disease isolates characterization – genetic characterization, diversity and evolution, region
    4. Understand incidence trend retrospectively and prospectively
  2. Disease impact – individual and community
    1. Short and long-term clinical consequences, complications 
    2. Direct and indirect costs and quality of life, social and psychological parameters
  3. Vaccine impact - in particular age cohort, setting or patient population
    1. Vaccine effectiveness 
    2. Vaccine impact on carriage dynamics – levels, density, transmission 
    3. Vaccination program impact on disease evolution and health economics
    4. Societal value of implementing meningococcal vaccination program
  4. Implementation
    1. Knowledge/awareness, attitudes/perceptions & behaviors/practices
    2. Vaccination preferences 
    3. Barriers and potential solutions 

Pneumococcal disease

Research areas to be considered for funding include:

  • Studies evaluating the burden of pneumococcal disease and serotype distribution prior to, or following, the implementation of PCV13 immunization programs. In addition, surveillance is conducted following the implementation of PCV10 in order to establish the remaining Burden of Disease (BoD) and serotype distribution:
    • Invasive Pneumococcal Disease (IPD)
    • Pneumonia (CAP, HCAP, HAP)
    • Acute Otitis Media (AOM) (children)
    • Exacerbations of chronic disease (e.g., CLD, CHF, others) either leading to hospitalization or following hospitalization
    • Long term declines in quality of life following pneumococcal syndromes (pneumonia, IPD)
    • Genetic evolution of pneumococci following use of PCV13 or PCV10
  • Nasopharyngeal carriage in children prior to, or following, the implementation of PCV immunization programs
  • Antibiotic resistant S. pneumoniae in children and/or adults prior to, or following, the implementation of PCV immunization programs
  • Association of pneumococcal disease with influenza or other viral illnesses in children and/or adults

Tick-borne Encephalitis

Research areas to be considered for Pfizer support include:

Identification of new TBE-endemic areas, virus-epidemiology

  • Tick surveillance, reservoir animals, human infection, human disease
  • Molecular characterization of TBEV and “virulence genes”
  • Characterization of circulating subtypes by region

Explore Burden of Disease:

  • Characterization of the clinical course or the natural course after infection
  • Diagnostics (e.g. adherence to guidelines, improvement of diagnostics, etc.)
  • Disease and sequelae in children and adults


  • Vaccine impact, effectiveness vaccine failures, Booster schedule (s)
  • Broad and cross neutralizing capacity
  • Closing vaccination gaps

New vaccination targets:

  • TBE in travelers (original clinical studies)
  • TBE in other exposed subjects (i.e., children, elderly)
  • Organisation of vaccination of travellers